Avastin use in high risk corneal transplantation.
BACKGROUND
Corneal neovascularization is a major risk factor for graft failure after corneal transplantation. The purpose of this study was to investigate the effect of subconjunctival, perilimbal, and/or intrastromal bevacizumab (Avastin) on corneal neovascularization in patients with penetrating keratoplasty (PKP).


METHODS
Fourteen eyes of 14 patients with high risk corneal transplantation and corneal neovascularization after PKP (nine men and five women with a mean age of 63 years) were included in this non-comparative interventional case series. Indications for PKP were: vascularized leukomas after herpetic keratitis and chemical burn, advanced pseudophakic bullous keratopathy with superficial and deep corneal vascularization, keratoconus, severe infection in hereditary corneal dystrophy, and failed corneal grafts. Subconjunctival, perilimbal, and/or intrastromal bevacizumab of dose of 2.5 mg/ 0.1 ml/ per affected quadrant was injected at the site of neovascularization in each patient at the end of surgery and/or at follow up visits. One or two injections were applied. At each visit a full eye examination with photo documentation was performed. Follow-up period was 2 to 8 months (mean 7.1 months).


RESULTS
Decrease of corneal neovascularization was observed in eleven patients (78.6%). Regression of neovascularization with fading of small vessels was demonstrated. Despite high- risk patient pool, twelve grafts (85.7%) remained transparent for the period of observation, and patients maintained good visual acuity. In two patients with initial graft rejection and vascularization, subconjunctival and perilimbal application of bevacizumab was beneficial in overcoming the corneal inflammation and initial rejection. No adverse reactions have been detected to date in patients with subconjunctival, perilimbal, and/or intrastromal injection of bevacizumab.


CONCLUSIONS
Bevacizumab is an efficient and safe additional treatment option for improvement of prognosis in high-risk corneal transplantation with pre- and postoperative corneal neovascularization.
Vassileva
Petja Ivanova
PI
University Eye Hospital "Prof. Pashev", 51 Emanuil Vaskidovich Street, Sofia, 1517, Bulgaria.
Hergeldzhieva
Tatyana Georgieva
TG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003228:Conjunctiva / Q000187:drug effects; D016510:Corneal Neovascularization / Q000517:prevention & control*; D003319:Corneal Stroma / Q000187:drug effects; D005260:Female; D006801:Humans; D007267:Injections; D015948:Keratoplasty, Penetrating; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D012307:Risk Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
J Cataract Refract Surg. 2007 Nov;33(11):1991-3
17964413
Acta Ophthalmol. 2008 May;86(3):322-8
17995975
Br J Ophthalmol. 2007 Jun;91(6):804-7
17179168
An Acad Bras Cienc. 2007 Sep;79(3):389-94
17768531
Cornea. 2008 Feb;27(2):142-7
18216566
Nat Med. 1995 Jan;1(1):27-31
7584949
Am J Transplant. 2004 May;4(5):678-85
15084160
Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2514-22
10937562
Graefes Arch Clin Exp Ophthalmol. 2007 Oct;245(10):1577-9
17458556